BIO stock forecast
Our latest prediction for Bio-Rad Laboratories, Inc.'s stock price was made on the Dec. 14, 2017 when the stock price was at 249.72$.
In the short term (2weeks), BIO's stock price should underperform the market by -0.14%. During that period the price should oscillate between -5.16% and +4.72%.
In the medium term (3months), BIO's stock price should underperform the market by -0.83%. During that period the price should oscillate between -13.52% and +14.56%.Get email alerts
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
At the moment the company generates 2294M USD in revenues.
On its last earning announcement, the company reported a profit of 42.25$ per share.
The book value per share is 155.49$
Three months stock forecastDec. 14, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|